Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

42 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Phase II study to evaluate the safety and efficacy of intravenous palonosetron (PAL) in primary malignant glioma (MG) patients receiving standard radiotherapy (RT) and concomitant temozolomide (TMZ).
Affronti ML, Woodring S, Allen K, Kirkpatrick J, Peters KB, Herndon JE 2nd, McSherry F, Healy PN, Desjardins A, Vredenburgh JJ, Friedman HS. Affronti ML, et al. Support Care Cancer. 2016 Oct;24(10):4365-75. doi: 10.1007/s00520-016-3276-1. Epub 2016 Jun 6. Support Care Cancer. 2016. PMID: 27271867 Clinical Trial.
Randomized open-label phase II trial of 5-day aprepitant plus ondansetron compared to ondansetron alone in the prevention of chemotherapy-induced nausea-vomiting (CINV) in glioma patients receiving adjuvant temozolomide.
Patel MP, Woodring S, Randazzo DM, Friedman HS, Desjardins A, Healy P, Herndon JE 2nd, McSherry F, Lipp ES, Miller E, Peters KB, Affronti ML. Patel MP, et al. Among authors: affronti ml. Support Care Cancer. 2020 May;28(5):2229-2238. doi: 10.1007/s00520-019-05039-x. Epub 2019 Aug 22. Support Care Cancer. 2020. PMID: 31440823 Clinical Trial.
Response to the letter to the Editor concerning manuscript entitled, "Randomized open-label phase II trial of 5-day aprepitant plus ondansetron compared to ondansetron alone in the prevention of chemotherapy-induced nausea-vomiting (CINV) in glioma patients receiving adjuvant temozolomide".
Affronti ML, Herndon JE 2nd, Patel MP. Affronti ML, et al. Support Care Cancer. 2020 Dec;28(12):5591-5592. doi: 10.1007/s00520-020-05726-0. Epub 2020 Sep 3. Support Care Cancer. 2020. PMID: 32885313 No abstract available.
2023 MASCC and ESMO guideline update for the prevention of chemotherapy- and radiotherapy-induced nausea and vomiting.
Herrstedt J, Clark-Snow R, Ruhlmann CH, Molassiotis A, Olver I, Rapoport BL, Aapro M, Dennis K, Hesketh PJ, Navari RM, Schwartzberg L, Affronti ML, Garcia-Del-Barrio MA, Chan A, Celio L, Chow R, Fleury M, Gralla RJ, Giusti R, Jahn F, Iihara H, Maranzano E, Radhakrishnan V, Saito M, Sayegh P, Bosnjak S, Zhang L, Lee J, Ostwal V, Smit T, Zilic A, Jordan K, Scotté F; participants of the MASCC/ESMO Consensus Conference 2022. Electronic address: [email protected]. Herrstedt J, et al. Among authors: affronti ml. ESMO Open. 2024 Feb;9(2):102195. doi: 10.1016/j.esmoop.2023.102195. Epub 2024 Jan 11. ESMO Open. 2024. PMID: 38458657 Free PMC article.
42 results